Designing antibodies as therapeutics
- PMID: 35868279
- DOI: 10.1016/j.cell.2022.05.029
Designing antibodies as therapeutics
Abstract
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit. These topics include enhancing antibodies for cancer, antibody delivery to organs such as the brain, gastrointestinal tract, and lungs, plus antibody developability challenges including immunogenicity risk assessment and mitigation and subcutaneous delivery. Machine learning has the potential, albeit as yet largely unrealized, for a transformative future impact on antibody discovery and engineering.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Both authors are current employees of Genentech, a member of the Roche Group, and Roche stockholders. The Roche Group develops and commercializes therapeutics including antibodies.
Similar articles
-
Applying computational protein design to therapeutic antibody discovery - current state and perspectives.Front Immunol. 2025 May 22;16:1571371. doi: 10.3389/fimmu.2025.1571371. eCollection 2025. Front Immunol. 2025. PMID: 40475769 Free PMC article. Review.
-
The Application of Machine Learning on Antibody Discovery and Optimization.Molecules. 2024 Dec 16;29(24):5923. doi: 10.3390/molecules29245923. Molecules. 2024. PMID: 39770013 Free PMC article. Review.
-
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.Nat Rev Drug Discov. 2024 Dec;23(12):898-913. doi: 10.1038/s41573-024-01051-x. Epub 2024 Oct 18. Nat Rev Drug Discov. 2024. PMID: 39424922 Review.
-
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.MAbs. 2014 May-Jun;6(3):577-618. doi: 10.4161/mabs.28421. Epub 2014 Mar 3. MAbs. 2014. PMID: 24589717 Free PMC article.
-
Engineering antibodies for cancer therapy.Annu Rev Chem Biomol Eng. 2011;2:53-75. doi: 10.1146/annurev-chembioeng-061010-114142. Annu Rev Chem Biomol Eng. 2011. PMID: 22432610 Review.
Cited by
-
Extracellular targeted protein degradation: an emerging modality for drug discovery.Nat Rev Drug Discov. 2024 Feb;23(2):126-140. doi: 10.1038/s41573-023-00833-z. Epub 2023 Dec 7. Nat Rev Drug Discov. 2024. PMID: 38062152 Review.
-
BrainBike peptidomimetic enables efficient transport of proteins across brain endothelium.RSC Chem Biol. 2023 Dec 11;5(1):7-11. doi: 10.1039/d3cb00194f. eCollection 2024 Jan 3. RSC Chem Biol. 2023. PMID: 38179197 Free PMC article.
-
Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data.Bioinformatics. 2023 Sep 2;39(9):btad446. doi: 10.1093/bioinformatics/btad446. Bioinformatics. 2023. PMID: 37478351 Free PMC article.
-
FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking.Nat Commun. 2025 Feb 7;16(1):1436. doi: 10.1038/s41467-025-56745-6. Nat Commun. 2025. PMID: 39920196 Free PMC article.
-
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening.MAbs. 2025 Dec;17(1):2502127. doi: 10.1080/19420862.2025.2502127. Epub 2025 May 10. MAbs. 2025. PMID: 40347482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical